A Phase 1 interventional study of LY900014 and Insulin Lispro in Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-30.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 18th largest by enrollment, is one of 8 that started in 2018, is one of 22 in phase 1, and was the 44th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–99
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 18+
By country, each count listing its studies:
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2002; this study’s year is marked. 8 started in 2018.
This study's enrollment of 80 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 69 interventional studies. Of the 60 that completed or were terminated, 33 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 69 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company: 4 open now, 6 under way, 4 of them phase 3. Of 66 finished, 49 (74%) have results posted.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is the 30th largest by enrollment of the 72 interventional ones that give a count, is one of 8 that started in 2018, is one of 33 in phase 1, and was the 46th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 1 studies by the year they started, since 2002.
1 of the studies testing Insulin Lispro in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, from their registry updates:
Among Eli Lilly and Company’s 75 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by injection under the skin. The study will assess how fast the active ingredient (insulin lispro or insulin aspart) gets into the blood stream and how long it takes the body to remove it. A test meal will be given to trial participants to assess the course of the blood sugar lowering effect of the investigational products. The safety and tolerability of LY900014 will also be assessed. Screening is required within 14 days prior to the lead in. For each participant, the study will last up to 91 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T1DM participants received a single, individualized, subcutaneous (SC) dose of LY900014.
Drug: LY900014
T1DM participants received a single, individualized, SC dose of insulin lispro.
Drug: Insulin Lispro
T1DM participants received a single, individualized, SC dose of insulin aspart.
Drug: Insulin Aspart
T1DM participants received a single, individualized, SC dose of insulin aspart.
Drug: Insulin Aspart
Healthy participants who received no study drug.
Administered SC
Also known as: Ultra-Rapid Lispro
Administered SC
Also known as: Humalog®, LY275585
Administered SC
Also known as: NovoRapid®
Administered SC
Also known as: Fiasp®
Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm
PK: Insulin Lispro or Insulin Aspart AUC(0-7h)
Time frame: 0 (predose), 1, 2, 3,5,10, 15, 20, 25, 30,35, 40, 45, 50, 55,60, 70, 90, 120, 150,180, 240, 300, 360 and 420 minutes postdose
Pharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)
PD: AUC(0-5h) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)
Time frame: Time Frame:-30, -15, 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240, and 300 minutes postdose
| Milestone | Type 1 Diabetes Mellitus (T1DM) Cohort 1 | T1DM Cohort 2 | T1DM Cohort 3 | T1DM Cohort 4 | Healthy Participants |
|---|---|---|---|---|---|
| Started | 17 | 16 | 18 | 17 | 12 |
| Received at least 1 dose of study drug | 17 | 16 | 18 | 17 | 0 |
| Completed | 17 | 16 | 18 | 17 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Type 1 Diabetes Mellitus (T1DM) Cohort 1 | T1DM Cohort 2 | T1DM Cohort 3 | T1DM Cohort 4 | Healthy Participants |
|---|---|---|---|---|---|
| Started | 17 | 16 | 18 | 17 | 12 |
| Received at least 1 dose of study drug | 17 | 16 | 18 | 17 | 0 |
| Completed | 17 | 16 | 18 | 17 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Type 1 Diabetes Mellitus (T1DM) Cohort 1 | T1DM Cohort 2 | T1DM Cohort 3 | T1DM Cohort 4 | Healthy Participants |
|---|---|---|---|---|---|
| Started | 17 | 16 | 18 | 17 | 12 |
| Received at least 1 dose of study drug | 17 | 15 | 18 | 17 | 0 |
| Completed | 17 | 15 | 18 | 17 | 12 |
| Not completed | 0 | 1 | 0 | 0 | 0 |
| Milestone | Type 1 Diabetes Mellitus (T1DM) Cohort 1 | T1DM Cohort 2 | T1DM Cohort 3 | T1DM Cohort 4 | Healthy Participants |
|---|---|---|---|---|---|
| Started | 17 | 15 | 18 | 17 | 12 |
| Received at least 1 dose of study drug | 17 | 15 | 18 | 17 | 0 |
| Completed | 17 | 15 | 18 | 17 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
PK: Insulin Lispro or Insulin Aspart AUC(0-7h)
| picomols times hour per Liter | LY900014 | Insulin Lispro (Humalog®) | Insulin Aspart (NovoRapid®) | Insulin Aspart (Fiasp®) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm | 786 ± 36 | 756 ± 37 | 938 ± 41 | 928 ± 36 |
PD: AUC(0-5h) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)
| milligrams times hour per deciliter | LY900014 | Insulin Lispro (Humalog®) | Insulin Aspart (NovoRapid®) | Insulin Aspart (Fiasp®) | Healthy Participants |
|---|---|---|---|---|---|
| Pharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) | 81.5 ± 212 | 141 ± 224 | 157 ± 243 | 101 ± 226 | 44.1 ± 32.5 |
Collected over up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY900014 | 0/68 (0%) | 0/68 (0%) | 0/68 (0%) |
| Insulin Lispro (Humalog®) | 0/67 (0%) | 0/67 (0%) | 0/67 (0%) |
| Insulin Aspart (Fiasp®) | 0/68 (0%) | 0/68 (0%) | 0/68 (0%) |
| Insulin Aspart (NovoRapid®) | 0/67 (0%) | 0/67 (0%) | 0/67 (0%) |
| Healthy Participants | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
All randomized participants that received at least 1 dose of study drug.
| Age, Categorical(Participants) | T1DM Cohort | Healthy Participants | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 61 | 12 | 73 |
| >=65 years | 7 | 0 | 7 |
| Sex: Female, Male(Participants) | T1DM Cohort | Healthy Participants | Total |
|---|---|---|---|
| Female | 17 | 0 | 17 |
| Male | 51 | 12 | 63 |
| Ethnicity (NIH/OMB)(Participants) | T1DM Cohort | Healthy Participants | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 67 | 12 | 79 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | T1DM Cohort | Healthy Participants | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 68 | 12 | 80 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | T1DM Cohort | Healthy Participants | Total |
|---|---|---|---|
| Germany | 68 | 12 | 0 |
| Body Mass Index (BMI)(kilograms per meter squared) | T1DM Cohort | Healthy Participants | Total |
|---|---|---|---|
| Mean | 25.82 ± 2.36 | 25.38 ± 1.80 | 25.38 ± 1.80 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Aug 2018, 4 months.
Results were first posted in Apr 2020, 1 year 8 months after primary completion.
Of 98 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 4 months is below that.
Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Lispro